StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Year

Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — International operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer Braftovi + Mektovi (encorafenib / binimetinib: 71.0% in FY2025.

Latest, FY2025
71.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)

Where the FY2025 figure comes from

“|| Braftovi/Mektovi | 716 | 607 | 18% | 18% | 672 | 580 | 16% | 45 | 27 | 67% | 71%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBraftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — International operational (constant-currency) YoY (%) (%)Year on yearSource
FY2025Dec 31, 202571.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Cite this data

StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-oper-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.